Related Experiment Video
Updated: Jul 4, 2026
11:01
Examining the Characteristics of Episodic Memory using Event-related Potentials in Patients with Alzheimer's Disease
Published on: August 30, 2011
Morphometric changes in the episodic memory network and tau pathologic features correlate with memory performance in
A M Fjell1, K B Walhovd, I Amlien
1Department of Psychology, University of Oslo, Oslo, Norway. andersmf@psykologi.uio.no
AJNR. American Journal of Neuroradiology
|June 12, 2008
Summary
Mild cognitive impairment (MCI) involves memory loss and brain changes. Brain structure and cerebrospinal fluid (CSF) biomarkers correlate with memory, suggesting atrophy in key brain areas contributes to MCI symptoms.
Area of Science:
- Neuroscience
- Neurology
- Biomarkers
Background:
- Mild cognitive impairment (MCI) often presents with memory deficits, but can affect other cognitive domains.
- Cerebrospinal fluid (CSF) biomarkers like tau proteins and amyloid beta 42 peptide are key in understanding MCI.
- Apolipoprotein E (APOE) allelic variation is also a factor in cognitive decline.
Purpose of the Study:
- To determine if CSF tau and amyloid beta 42 levels explain cerebral cortex thinning in MCI patients.
- To investigate the relationship between brain morphometry, CSF biomarkers, APOE, and episodic memory function in MCI.
Main Methods:
- Magnetic resonance imaging (MRI) was used to estimate hippocampal volume and cortical thickness in MCI patients and controls.
- Regions of interest (ROIs) within the episodic memory network were analyzed for atrophy.
- Relationships between morphometry, CSF biomarkers, APOE, and memory were assessed in two independent MCI samples.
Main Results:
- MCI patients with abnormal CSF biomarkers showed hippocampal atrophy.
- Cortical thinning was observed in MCI patients regardless of CSF biomarker status.
- Brain morphometry strongly correlated with memory performance across MCI samples.
Conclusions:
- Hippocampal volume differences were specific to MCI patients with pathological CSF biomarkers.
- Cortical thickness differences were present in MCI patients even without pathological CSF biomarkers.
- Atrophy in the episodic memory network is linked to memory impairment in MCI.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...